Taken together, these results provide a novel immunotherapeutic potential by targeting TOP1 with TLC388 maximizes the clinical benefit to poorly immunogenic CRC patients in combination with radiotherapy as well as immunotherapy. This evidence concerns the gene TOP1 and colorectal carcinoma.